PARP1 inhibitors are a class of drugs that target the enzyme poly (ADP-ribose) polymerase 1 (PARP1). PARP1 is involved in DNA repair processes, specifically base excision repair. The mechanism of action of PARP1 inhibitors involves blocking the activity of PARP1, preventing it from repairing damaged DNA. This leads to the accumulation of DNA damage and ultimately causes cell death, particularly in cancer cells that rely heavily on PARP1-mediated DNA repair pathways. PARP1 inhibitors are primarily used in the treatment of certain types of cancer, such as breast, ovarian, and prostate cancers. They have shown particular efficacy in cancers with defects in the DNA repair pathway, such as those with BRCA mutations. Additionally, PARP1 inhibitors are being investigated for their potential use in other conditions, including neurodegenerative diseases and cardiovascular disorders. According to the Centers for Diseases Control and Prevention, breast cancer is the second most common cancer among women in the USA, which accounts for 264,000 new cases and 42000 deaths every year. Companies such as AstraZeneca, Jeil, AbbVie, J&J, Merck (MSD), BeiGene, GSK, Impact Therapy, Ildong, Medison, National OncoVenture, Pfizer, Sanofi, Takeda currently cater to breast cancer, prostate cancer, peritoneal cancer segments. Lynparza (Olaparib) is one of the prominent drugs by Merck (MSD), AstraZeneca which is being used to treat sarcoma and breast carcinoma. Moreover, Zejula (niraparib) by GSK, J&J, Takeda, and Talzenna (Talazoparib) by Pfizer are other prominent drugs that are used extensively in cases of Glioblastoma and leukemia respectively, apart from getting used in before-mentioned indications. Moreover, many companies are coming up with new molecules in this space. For instance, Abbvie is one such company that is currently conducting a clinical trial of the drug ABT-888 for the treatment of endocrine gland neoplasm and breast cancer.
Key Developments
- In May 2023, Gilead acquired XinThera, through which they strengthened their early pipeline in oncology by getting the rights of precision small molecules focused on PARP1 and MK2 inhibitors.
- In June 2023, Eikon Therapeutics and Impact Therapeutics entered into a global licensing and collaboration agreement For PARP1 selective inhibitor IMP1734, which is anticipated to enter into Phase I clinical study in 2023. Under the collaboration agreement, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan)
- In September 2022, Merck announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next generation highly selective and brain penetrant PARP1 Inhibitor, NMS-293 development.
Approved PARP1 Inhibitors
- Niraparib (Zejula)/GSK, J&J, Takeda
- Olaparib (Lynparza)/ Merck (MSD), AstraZeneca
- Talazoparib (Talzenna)/Pfizer
- Rucaparib (Rubraca)/Clovis
Pipeline Drugs - PARP1 Inhibitor
- Lynparza (Olaparib) / Merck (MSD), Astrazeneca
- Zejula (Niraparib) / GSK, J&J, Takeda
- Talzenna (Talazoparib) / Pfizer
- Veliparib (Abt-888) / AbbVie
- Rubraca (Rucaparib) / Clovis
- Airuiyi (Fluzoparib) / Jiangsu Hengrui Pharma
- Partruvix (Pamiparib) / Emd Serono, Beigene
- Iniparib (Bsi 201) / Sanofi
- Senaparib (Imp4297) / Impact Therapy
- Azd5305 / Astrazeneca
- Stenoparib (2x-121) / Allarity Therap, Oncoheroes
- Sc10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
- Venadaparib (Nov 1401) / National Oncoventure, Ildong
- Amelparib (Jpi-289) / Jeil
- Nesuparib (Jpi-547) / Jeil
- NMS-293 / Nerviano Medical Sciences, Merck (MSD)
- TQB3823 / Sino Biopharm
- ABT-767 / AbbVie
- AMXI-5001 / AtlasMedx
- AZD9574 / AstraZeneca
- Akeega (abiraterone/niraparib)
- HS-10502 / Jiangsu Hansoh Pharma
- HTMC0435 / Shanghai Huilun
- HWH340 / WuXi AppTec, Hubei Bio
- RP12146 / Incozen Therap, Rhizen
- TSL-1502 / Tasly
- Simmiparib (SMOCL-9112) / Shanghai Acebright Pharma
Clinical Activity and Development of PARP1 Inhibitor
In the PARP1 inhibitor space, approximately 36 companies are focusing on 345 disease indications, and more than 600 clinical trials are being conducted in this category of drugs. For instance,
- In February 2023, Janssen presented updated data demonstrating improved outcomes from the use of niraparib in combination with Abiraterone Acetate plus Prednisone as a first-line therapy in patients with BRCA-positive metastatic castration-resistant prostate cancer.
- In February 2019, Janssen announced preliminary results from the phase 2 Galahad study in adults with metastatic castration-resistant prostate cancer and DNA-repair pathway defects (DRD). Data showed Niraparib demonstrated an objective response rate of approximately 40 percent in patients with metastatic castration-resistant prostate cancer and DNA-repair pathway defects, specifically BRCA1/2.
Target Indication Analysis of PARP1 Inhibitors
The PARP1 inhibitors are primarily used to treat breast cancer, prostate cancer, and fallopian tube cancer. PARP1 inhibitors also help to prevent ovarian epithelial cancer. For instance, Veliparib is one drug by AbbVie which is under trial for the treatment of ovarian epithelial cancer. In the treatment of fallopian tube cancer, PARP1 inhibitor Nirapirib is used widely. Through research and development, the indications in which PARP1 inhibitors can be used are getting expanded. For instance, PARP1 inhibitors are now under clinical trial for the treatment of rhabdoid tumors.
Regional Analysis of PARP1 Inhibitors
PARP1 Inhibitors Market
The global PARP1 inhibitors market is segmented into five major regions that are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The North American PARP1 inhibitor market reveals a promising landscape for the pharmaceutical industry. The market in North America is driven by factors such as the high prevalence of cancer, advanced healthcare infrastructure, and a strong emphasis on research and development. Major countries contributing to the North American market for PARP1 inhibitors include the United States and Canada. The United States, being a frontrunner in the healthcare industry, holds a significant share of the market. According to the WHO, prostate cancer is the second leading cause of cancer death in men in the United States, it is estimated that 34700 deaths from this disease will occur in the United States in 2023. The country boasts a robust pharmaceutical sector, extensive clinical trial networks, and a large patient population. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for PARP1 inhibitors. These countries are increasingly adopting PARP1 inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the PARP1 inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, United Kingdom, Italy, and Spain. These countries have a robust pharmaceutical industry and a high prevalence of cancer, which is a key indication for PARP1 inhibitors. The market is characterized by a well-established healthcare infrastructure, strategic collaborations between pharmaceutical companies, and growing awareness about targeted therapies. With the ongoing advancements in drug development and personalized medicine approaches, the Europe regional market for PARP1 inhibitors is expected to continue its upward trajectory.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
The approved molecules of PARP1 inhibitors are Lynparza (olaparib), Zejula (niraparib), Talzenna (talazoparib), and Rubraca (rucaparib).
The increasing prevalence of breast cancer, advanced healthcare infrastructure, and a strong emphasis on research and development are the primary drivers for market growth.
The major players in this space are AstraZeneca, AbbVie, J&J, GSK, Merck (MSD), BeiGene, Pfizer, Sanofi, and Takeda
The emergence of alternative treatment options, such as other targeted therapies or combination therapies, and stringent reimbursement policies in some regions as well as the high cost of drugs can limit their use and impact market growth.
- AstraZeneca
- Jeil
- AbbVie
- J&J
- Merck (MSD)
- Allarity Therap
- AtlasMedx
- BeiGene
- BioMarin
- Clovis
- EMD Serono
- GSK
- Hubei Bio
- IMPACT Therap
- Ildong
- Incozen Therap
- Jiangsu Hansoh Pharma
- Jiangsu Hengrui Pharma
- Jiangxi Qingfeng Pharma
- Mayo Clinic
- Medison
- National OncoVenture
- Nerviano Medical Sciences
- Oncoheroes
- Pfizer
- Rhizen
- Sanofi
- Shanghai Acebright Pharma
- Shanghai De Novo Pharmatech
- Shanghai Huilun
- Shanghai Junshi Biosci
- Sino Biopharm
- Takeda
- Tasly
- WuXi AppTec
- ZAI Lab